NATCO Pharma Limited
NSE: NATCOPHARM BSE: NATCOPHARM
NSE
829.80
2.20 (0.27%)
Prev Close
827.6
Open Price
834.4
Volume
383,129
Today Low / High
816 / 834.8
52 WK Low / High
726.8 / 1639
Range
788 - 871
BSE
829.00
2.15 (0.26%)
Prev Close
826.85
Open Price
837.85
Volume
18,350
Today Low / High
816 / 837.85
52 WK Low / High
660.05 / 1638.35
Range
788 - 870
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 829.8 (target range: 788 - 871), reflecting a change of 2.2 (0.26583%). On the BSE, it is listed at 829 (target range: 788 - 870), showing a change of 2.15 (0.26002%). Both the NSE and BSE data indicate positive movement, suggesting the stock is on an upward trend. This could be an attractive opportunity for investors looking for growth.
21 Apr
834.40
-0.55%
17 Apr
826.60
0.12%
16 Apr
805.75
2.59%
15 Apr
786.00
2.28%
11 Apr
783.40
-1.01%
09 Apr
770.15
-3.07%
08 Apr
788.95
-2.38%
07 Apr
729.95
4.92%
04 Apr
840.00
-5.15%
03 Apr
819.90
2.03%
02 Apr
807.00
-0.06%
01 Apr
798.75
0.78%
28 Mar
822.85
-2.93%
27 Mar
822.05
0.09%
26 Mar
824.55
-0.36%
25 Mar
844.00
-2.26%
24 Mar
831.95
-0.25%
NATCO Pharma Limited Graph
NATCO Pharma Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for NATCO Pharma Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 829.80, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 829.00 | 837.29 | 753.56 - 921.02 |
| 845.58 | 676.46 - 1,014.70 | ||
| 853.87 | 597.71 - 1,110.03 | ||
| Bearish Scenario | 829.00 | 820.71 | 738.64 - 902.78 |
| 812.42 | 649.94 - 974.90 | ||
| 804.13 | 562.89 - 1,045.37 |
Overview of NATCO Pharma Limited
ISIN
INE987B01026
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
1,025,221
Market Cap
148,625,361,828
Last Dividend
6
Official Website
IPO Date
1996-01-01
DCF Diff
-915.57
DCF
1,747
Financial Ratios Every Investor Needs
Stock Dividend of NATCOPHARM
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2025-02-18 | February 18, 25 | 1.5 | 1.5 | 2025-02-18 | 2025-03-14 | |
| 2024-11-27 | November 27, 24 | 1.5 | 1.5 | 2024-11-27 | 2024-12-04 | |
| 2024-08-23 | August 23, 24 | 3 | 3 | 2024-08-23 | 2024-09-11 | |
| 2024-02-26 | February 26, 24 | 1.25 | 1.25 | 2024-02-26 | 2024-03-04 | |
| 2023-11-24 | November 24, 23 | 1.25 | 1.25 | 2023-11-24 | 2023-12-14 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 4,002.00 Cr | 862.50 Cr | 3,139.50 Cr | 0.7845 | 121.10 Cr | 115.30 Cr | 2,596.20 Cr | 1,388.30 Cr | 77.34 | 1,879.50 Cr | 0.3469 |
| 2023-03-31 | 2,707.10 Cr | 627.30 Cr | 2,079.80 Cr | 0.7683 | 90.20 Cr | 106.90 Cr | 876.40 Cr | 715.30 Cr | 39.18 | 1,040.20 Cr | 0.2642 |
| 2022-03-31 | 1,904.90 Cr | 681.50 Cr | 1,223.40 Cr | 0.6422 | 176.90 Cr | 81.80 Cr | 219.90 Cr | 170.00 Cr | 9.32 | 362.50 Cr | 0.0892 |
| 2021-03-31 | 1,690.30 Cr | 607.90 Cr | 1,082.40 Cr | 0.6404 | 147.30 Cr | 56.50 Cr | 501.00 Cr | 440.90 Cr | 24.20 | 709.80 Cr | 0.2608 |
| 2020-03-31 | 1,887.80 Cr | 510.00 Cr | 1,377.80 Cr | 0.7298 | 63.30 Cr | 58.70 Cr | 491.20 Cr | 460.80 Cr | 25.33 | 690.00 Cr | 0.2441 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 70.40 Cr | 6,906.30 Cr | 1,053.20 Cr | 5,853.1000 Cr | 386.10 Cr | 315.70 Cr | 791.70 Cr | 2,435.00 Cr | 0.00 Cr | 0.00 Cr | 139.80 Cr | 972.8000 Cr |
| 2023-03-31 | 131.90 Cr | 5,657.40 Cr | -3,480.00 Cr | 4,873.8000 Cr | 166.70 Cr | 34.80 Cr | 742.90 Cr | 2,303.40 Cr | 112.90 Cr | 87.00 Cr | -925.90 Cr | 683.1000 Cr |
| 2022-03-31 | 111.10 Cr | 5,109.10 Cr | 845.50 Cr | 4,263.6000 Cr | 432.00 Cr | 320.90 Cr | 762.00 Cr | 2,308.40 Cr | 87.70 Cr | 1.30 Cr | -565.10 Cr | 710.4000 Cr |
| 2021-03-31 | 25.80 Cr | 4,791.90 Cr | 668.50 Cr | 4,121.6000 Cr | 283.90 Cr | 258.10 Cr | 798.20 Cr | 2,237.20 Cr | 1.30 Cr | 1.10 Cr | -625.00 Cr | 525.6000 Cr |
| 2020-03-31 | 19.80 Cr | 4,587.80 Cr | 803.10 Cr | 3,773.5000 Cr | 329.40 Cr | 309.60 Cr | 558.00 Cr | 2,093.70 Cr | 8.50 Cr | 0.80 Cr | -799.10 Cr | 685.3000 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 1,211.6000 Cr | -1,032.7000 Cr | -246.9000 Cr | 852.9000 Cr | -61.5000 Cr | 70.4000 Cr | -339.4000 Cr | 1,388.3000 Cr | 197.8000 Cr | -170.8000 Cr | 42.4000 Cr |
| 2023-03-31 | 849.1000 Cr | -477.1000 Cr | -363.0000 Cr | 643.5000 Cr | 20.8000 Cr | 131.9000 Cr | -205.6000 Cr | 861.9000 Cr | -239.0000 Cr | -100.4000 Cr | 19.1000 Cr |
| 2022-03-31 | 46.5000 Cr | -5.3000 Cr | 34.8000 Cr | -196.2000 Cr | 85.3000 Cr | 111.1000 Cr | -242.7000 Cr | 202.2000 Cr | -2.4000 Cr | -82.2000 Cr | 56.4000 Cr |
| 2021-03-31 | 298.8000 Cr | -103.3000 Cr | -185.7000 Cr | 44.2000 Cr | 6.0000 Cr | 25.8000 Cr | -254.6000 Cr | 579.6000 Cr | -48.4000 Cr | -113.9000 Cr | -240.2000 Cr |
| 2020-03-31 | 417.3000 Cr | -167.0000 Cr | -250.8000 Cr | 58.7000 Cr | -8.5000 Cr | 19.8000 Cr | -358.6000 Cr | 568.7000 Cr | -80.1000 Cr | -153.6000 Cr | -28.9000 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2024-12-31 | 474.80 Cr | 82.80 Cr | 392.00 Cr | 0.8256 | -8.20 Cr | 133.00 Cr | 7.43 | 215.10 Cr | 0.2801 |
| 2024-09-30 | 1,371.10 Cr | 177.60 Cr | 1,193.50 Cr | 0.8705 | 758.50 Cr | 677.30 Cr | 37.81 | 868.10 Cr | 0.4940 |
| 2024-06-30 | 1,362.60 Cr | 366.30 Cr | 996.30 Cr | 0.7312 | 760.70 Cr | 668.50 Cr | 37.32 | 852.90 Cr | 0.4906 |
| 2024-03-31 | 1,068.30 Cr | 340.60 Cr | 727.70 Cr | 0.6812 | 441.80 Cr | 386.30 Cr | 21.56 | 539.30 Cr | 0.3616 |
| 2023-12-31 | 758.60 Cr | 162.20 Cr | 596.40 Cr | 0.7862 | 260.90 Cr | 212.70 Cr | 11.88 | 305.10 Cr | 0.2804 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2024-09-30 | 104.60 Cr | 2,358.80 Cr | 2,463.40 Cr | 0.00 Cr | 774.60 Cr | 5,001.50 Cr | 2,538.20 Cr | 8,244.70 Cr | 1,087.90 Cr |
| 2024-06-30 | 0.00 Cr | 0.00 Cr | 1,849.20 Cr | 0.00 Cr | 0.00 Cr | 1,849.20 Cr | 0.00 Cr | 0.00 Cr | -5,853.10 Cr |
| 2024-03-31 | 952.90 Cr | 443.50 Cr | 1,396.40 Cr | 1,188.90 Cr | 700.50 Cr | 4,023.50 Cr | 2,435.00 Cr | 6,906.30 Cr | 1,053.20 Cr |
| 2023-12-31 | -1,215.60 Cr | 2,431.20 Cr | 1,215.60 Cr | 0.00 Cr | 0.00 Cr | 1,215.60 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-09-30 | 104.00 Cr | 1,111.60 Cr | 1,215.60 Cr | 1,119.80 Cr | 709.80 Cr | 3,349.70 Cr | 2,353.10 Cr | 6,254.00 Cr | 960.50 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2024-06-30 | 668.50 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-03-31 | 386.30 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-12-31 | 212.70 Cr | 88.40 Cr | 0.00 Cr | 0.00 Cr | 88.40 Cr | 807.90 Cr | 719.50 Cr | 0.00 Cr | 88.40 Cr |
| 2023-09-30 | 369.00 Cr | 87.20 Cr | 0.00 Cr | 0.00 Cr | 87.20 Cr | 719.50 Cr | 632.30 Cr | 0.00 Cr | 87.20 Cr |
| 2023-06-30 | 420.30 Cr | 87.00 Cr | 0.00 Cr | 0.00 Cr | 87.00 Cr | 223.60 Cr | 136.60 Cr | 0.00 Cr | 87.00 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| 2015-11-26 | November 26, 15 | 5:1 |
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,744.90 | ₹4,186,497,390,360.00 | ₹1,539,404.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹5,891.50 | ₹1,564,008,080,155.00 | ₹717,304.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,254.60 | ₹1,101,504,496,478.00 | ₹168,941.00 |
| Mankind Pharma Limited | MANKIND | ₹2,588.40 | ₹1,067,918,241,168.00 | ₹342,053.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,177.40 | ₹980,907,622,968.00 | ₹1,938,682.00 |
| Lupin Limited | LUPIN | ₹2,009.20 | ₹917,330,458,276.00 | ₹966,589.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹845.35 | ₹850,616,530,500.00 | ₹1,860,605.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,201.20 | ₹697,658,929,968.00 | ₹653,310.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,000.40 | ₹597,872,826,000.00 | ₹97,948.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹1,368.80 | ₹386,259,126,032.00 | ₹2,163,260.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,423.80 | ₹361,224,068,436.00 | ₹163,712.00 |
| Laurus Labs Limited | LAURUSLABS | ₹640.35 | ₹345,310,338,375.00 | ₹1,671,228.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,679.20 | ₹334,664,498,320.00 | ₹44,703.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,202.20 | ₹306,037,994,912.00 | ₹330,131.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,658.70 | ₹258,221,804,814.00 | ₹100,079.00 |
| Piramal Enterprises Limited | PEL | ₹1,039.85 | ₹234,462,986,345.00 | ₹552,041.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,401.40 | ₹227,698,028,558.00 | ₹264,593.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹8,727.50 | ₹218,187,500,000.00 | ₹13,476.00 |
| Eris Lifesciences Limited | ERIS | ₹1,382.90 | ₹188,299,218,053.00 | ₹81,150.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹13,136.00 | ₹168,533,566,400.00 | ₹53,273.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹849.65 | ₹167,009,863,405.00 | ₹223,768.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹829.80 | ₹148,625,361,828.00 | ₹383,129.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹915.95 | ₹145,893,560,183.00 | ₹228,298.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹1,906.70 | ₹144,931,500,763.00 | ₹146,966.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Granules India Limited | GRANULES | ₹480.20 | ₹116,469,494,344.00 | ₹1,207,487.00 |
| Procter & Gamble Health Limited | PGHL | ₹5,223.50 | ₹86,706,866,654.00 | ₹3,571.00 |
| FDC Limited | FDC | ₹430.60 | ₹70,106,024,754.00 | ₹67,489.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹712.85 | ₹64,608,888,867.00 | ₹374,808.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹658.10 | ₹64,356,197,871.00 | ₹163,074.00 |
| Strides Pharma Science Limited | STAR | ₹640.75 | ₹59,053,256,433.00 | ₹243,236.00 |
| Innova Captab Limited | INNOVACAP | ₹915.85 | ₹52,409,452,141.00 | ₹37,786.00 |
| Hikal Limited | HIKAL | ₹423.80 | ₹52,254,857,850.00 | ₹371,223.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹152.84 | ₹49,599,942,480.00 | ₹505,473.00 |
| Unichem Laboratories Limited | UNICHEMLAB | ₹633.90 | ₹44,630,236,620.00 | ₹75,809.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹799.75 | ₹40,562,604,224.00 | ₹101,985.00 |
| Sequent Scientific Limited | SEQUENT | ₹148.17 | ₹37,087,247,340.00 | ₹527,793.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹2,179.20 | ₹36,041,821,488.00 | ₹10,217.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹349.90 | ₹35,087,098,650.00 | ₹40,163.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹361.65 | ₹33,007,795,500.00 | ₹101,872.00 |
| Morepen Laboratories Limited | MOREPENLAB | ₹53.91 | ₹29,540,183,967.00 | ₹4,747,370.00 |
| Suven Life Sciences Limited | SUVEN | ₹127.13 | ₹27,723,712,024.00 | ₹173,057.00 |
| Alembic Limited | ALEMBICLTD | ₹105.35 | ₹27,051,965,791.00 | ₹436,085.00 |
| Solara Active Pharma Sciences Limited | SOLARA | ₹520.70 | ₹25,021,207,514.00 | ₹37,558.00 |
Key Executives
Senior Vice President of HR & Organisational Development
Mr. A. Lakshminarayana
Gender: male
Year Born: 1963
Executive Vice President of Corporate Affairs, Legal, Secretarial & Estate Management
N. Sadasiva Rao
Gender: Not Specified
Year Born:
MD & Chairman
Mr. Venkaiah Chowdary Nannapaneni M. Pharm, MS.
Gender: male
Year Born: 1945
Company Secretary & Compliance Officer
Mr. Chekuri Venkat Ramesh C.S.
Gender: male
Year Born:
Executive Vice President of Corporate Engineering Services & Whole Time Director
Mr. Potluri Sivaramakrishna Prasad
Gender: male
Year Born: 1958
Chief Executive Officer & Vice Chairman
Mr. Rajeev Nannapaneni
Gender: male
Year Born: 1977
Vice President & Head of Operations
Nadella Malleswara Rao
Gender: Not Specified
Year Born:
Chief Financial Officer
Mr. S. V. V. N. Appa Rao
Gender: male
Year Born:
President of Technical Affairs & Whole Time Director
Dr. Donthineni Linga Rao M.D.
Gender: Not Specified
Year Born: 1952
Vice President of Marketing & Sales - Domestic
James Rajakumar
Gender: Not Specified
Year Born:
FAQs about NATCO Pharma Limited
Who is the CEO of the company?
The CEO is Mr. Rajeev Nannapaneni.
What is the current market price of the stock?
The current price is ₹829.80.
What is the 52-week price range?
The range is ₹726.8-1639.
What is the market capitalization of the company?
The market capitalization is ₹14,862.54 crores.
What is the dividend yield?
The dividend yield is 0.72%.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 7.96.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of NATCO Pharma Limited (ISIN: INE987B01026) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹14,862.54 crores and an average daily volume of 1,025,221 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹6.